These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 14679183)

  • 1. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.
    Jones SC; Murphy GF; Friedman TM; Korngold R
    J Clin Invest; 2003 Dec; 112(12):1880-6. PubMed ID: 14679183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses.
    Korngold R
    Bone Marrow Transplant; 1992 May; 9(5):355-64. PubMed ID: 1352163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vbeta spectratype analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate.
    Friedman TM; Statton D; Jones SC; Berger MA; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2001; 7(1):2-13. PubMed ID: 11215694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens.
    Fujii H; Ivison SM; Shimizu H; Kajiwara R; Kariminia A; Yan M; Dutz JP; Schultz KR
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):546-56. PubMed ID: 22178962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
    Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
    Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
    Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunodominant CD4+ T cell receptor Vbeta repertoires involved in graft-versus-host disease responses to minor histocompatibility antigens.
    Berger MA; Korngold R
    J Immunol; 1997 Jul; 159(1):77-85. PubMed ID: 9200441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell receptor V(alpha) usage by effector CD4+Vbeta11+ T cells mediating graft-versus-host disease directed to minor histocompatibility antigens.
    DiRienzo CG; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):265-76. PubMed ID: 17317580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease.
    Schultz KR; Bader S; Paquet J; Li W
    Blood; 1995 Dec; 86(11):4344-52. PubMed ID: 7492796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens.
    Korngold R; Leighton C; Mobraaten LE; Berger MA
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):57-64. PubMed ID: 9267665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graft-versus-host disease.
    DiRienzo CG; Murphy GF; Jones SC; Korngold R; Friedman TM
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):818-27. PubMed ID: 16864052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease.
    Friedman TM; Gilbert M; Briggs C; Korngold R
    J Immunol; 1998 Jul; 161(1):41-8. PubMed ID: 9647205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.
    Schultz KR; Paquet J; Bader S; HayGlass KT
    Bone Marrow Transplant; 1995 Aug; 16(2):289-95. PubMed ID: 7581150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.
    Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ
    J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.